https://scholars.lib.ntu.edu.tw/handle/123456789/161502
Title: | EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer | Authors: | Kao, Hsiang-Fong Lin, Chia-Chi Yang, James Chih-Hsin |
Keywords: | afatinib;cetuximab;erlotinib;gefitinib;molecular targeted therapies;non-small-cell lung cancer;personalized medicine | Issue Date: | 2013 | Start page/Pages: | 991-1003 | Source: | Future Oncology | Abstract: | Drugs that target the EGFR have a major impact on the treatment of advanced non-small-cell lung cancer (NSCLC). EGFR mutations in NSCLC are associated with a dramatic and sustained response to EGFR tyrosine kinase inhibitors (TKIs). This review summarizes the results of randomized trials using EGFR TKIs or EGFR monoclonal antibodies with chemotherapy in the first-line setting, and discusses several unresolved issues regarding the use of the EGFR TKIs as the first-line therapy in advanced NSCLC. |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/280061 | DOI: | 10.2217/FON.13.56 |
Appears in Collections: | 腫瘤醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.